Table 2: Urinary markers predicting BCG treatment outcome. The markers are ordered from the most studied to the less, and, within each marker, the studies are ordered by quality score.

Marker AuthorQuality   n Treatment schemeImpactOutcome
Rec(P)RFS
(P/HR (95% CI))
Prog(P)PFS
(P/HR (95% CI))

IL-8Sagnak et al., [54]6/841iBCGX0.006/2.98 (1.02–8.72) XX
Kumar et al., [57]5/826iBCG+0.001XXX
Sanchez-Carbayo et al., [58]5/815iBCGNoneNSXXX
Jackson et al., [60]5/834iBCGNoneNS/NS*XXX
Rabinowitzir et al., [62]5/846iBCGNoneNSXXX
Shintani et al., [55]4/820iBCGNoneNSXXX
Watanabe et al., [56]4/820iBCG+<0.050.013/NS*XX
Thalmann et al., [59]4/817iBCG+0.0209XXX
Thalmann et al., [61]4/820iBCG+0.0002XXX

IL2Saint et al., [64]5/837iBCG+X0.0009XNS
Sanchez-Carbayo et al., [58]5/815iBCG+0.041XXX
Jackson, [60]5/834iBCGNoneNS/NS*XXX
De Reijke et al., [66]5/823iBCG+0.003XXX
Saint et al., [63]4/839mBCG+X0.01X0.01
Watanabe et al., [56]4/820iBCG+<0.010.0003/0.37 (0.03–0.895)*XX
Saint et al., [65]4/819iBCG + iBCGNone/+NS/
<0.05
XXX

IFN-γSaint et al., [64]5/837iBCGNoneXNSXNS
Jackson, [60]5/834iBCGNoneNS/NS*XXX
Shintani et al., [55]4/820iBCGNoneNSXXX
Watanabe et al., [56]4/820iBCGNoneNSNS/NS*XX
Saint et al., [65]4/819iBCG + iBCG+/None<0.05/
NS
XXX

TNF-αSanchez-Carbayo et al., [58]5/815iBCGNoneNSXXX
Jackson, [60]5/834iBCG+NS/
<0.05*
XXX
De Reijke et al., [66]5/823iBCG+0.025XXX
Shintani et al., [55]4/820iBCGNoneNSXXX
Watanabe et al., [56]4/820iBCG+<0.050.012/NS*XX
IL-10Saint et al., [64]5/837iBCGNoneXNSXNS
Jackson, [60]5/834iBCGNoneNS/NS*XXX
Saint et al., [63]4/839mBCGNoneXNSXNS
Watanabe et al., [56]4/820iBCG+<0.010.009/NS*XX
Saint et al., [65]4/819iBCG + iBCGNoneNSXXX

IL-6Sanchez-Carbayo et al., [58]5/815iBCGNoneNSXXX
Jackson, [60]5/834iBCGNoneNS/NS*XXX
De Reijke et al., [66]5/823iBCG+0.04XXX
Watanabe et al., [56]4/820iBCG+<0.050.023/NS*XX

Urovysion (FISH)Whitson et al., [100]6/848mBCGX<0.01/6.7 (2.1–22.1)*XX
 +posttreatSavic et al., [101]5/868iBCGX<0.001/5.6 (2.5–12.2)*XX
Mengual, [102]5/865iBCGX0.015/2.7(1.18–6.15)*XX
 +pretreatKipp et al., [103]5/837iBCGXNS/3.3(1.3–8.5)*XNS/NS*
 +posttreatX<0.001/4.6 (1.9–11.1)X0.001/9.4 (1.9–45.3)

IL-12Jackson, [60]5/834iBCGNoneNS/NS*XXX
Shintani et al., [55]4/820iBCGNoneNSXXX
Watanabe et al., [56]4/820iBCGNoneNSNS/NS*XX

IL-1βDe Reijke et al., [66]5/823iBCGNoneNSXXX
Shintani et al., [55]4/820iBCGNoneNSXXX
Watanabe et al., [56]4/820iBCGNoneNSNS/NS*XX

GM-CSFJackson, [60]5/834iBCG<0.05/
<0.05*
XXX
Shintani et al., [55]4/820iBCGNoneNSXXX

WBCSaint et al., [104]5/872mBCG+X0.009XX
Shintani et al., [55]4/820iBCGNoneNSXXX

G-CSFShintani et al., [55]4/820iBCGNoneNSXXX

FNDanişman et al., [69]5/838iBCGNoneNSXXX

IL-4Jackson, [60]5/834iBCGNoneNS/NS*XXX

sICAM-1Jackson, [60]5/834iBCG+NS/
<0.05*
XXX
sCD14Jackson, [60]5/834iBCGNS/
<0.05*
XXX

SurvivinHausladen, [68]4/823iBCG<0.05XXX

IL-18Thalmann et al., [59]4/817iBCG+0.0464XXX

iBCG: induction BCG scheme only.
mBCG: maintenance BCG scheme.
−: negative impact, marker associated with a poor BCG response.
+: positive impact, marker associated to a better BCG response.
Rec: recurrence; P value for recurrence.
RFS: recurrence-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
Prog: progression; P value for progression.
PFS: progression-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
NS: no statistical significance.
X: not evaluated.
*all analysed variables (indepent prognostic factor).
adjusted for BCG-related complications, tumour stage, and grade.